Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease.

Endothelial protein C receptor (EPCR) and thrombomodulin (TM) are expressed at high levels in the resting microvasculature and convert protein C (PC) into its activated form, which is a potent anticoagulant and antiinflammatory molecule. Here we provide evidence that in Crohn disease (CD) and ulcerative colitis (UC), the 2 major forms of inflammatory bowel disease (IBD), there was loss of expression of endothelial EPCR and TM, which in turns caused impairment of PC activation by the inflamed mucosal microvasculature. In isolated human intestinal endothelial cells, administration of recombinant activated PC had a potent antiinflammatory effect, as demonstrated by downregulated cytokine-dependent cell adhesion molecule expression and chemokine production as well as inhibited leukocyte adhesion. In vivo, administration of activated PC was therapeutically effective in ameliorating experimental colitis as evidenced by reduced weight loss, disease activity index, and histological colitis scores as well as inhibited leukocyte adhesion to the inflamed intestinal vessels. The results suggest that the PC pathway represents a new system crucially involved in governing intestinal homeostasis mediated by the mucosal microvasculature. Restoring the PC pathway may represent a new therapeutic approach to suppress intestinal inflammation in IBD.

[1]  S. Danese,et al.  Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens , 2007, The American Journal of Gastroenterology.

[2]  S. Danese,et al.  Etiopathogenesis of inflammatory bowel diseases. , 2006, World journal of gastroenterology.

[3]  A. Gasbarrini,et al.  Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. , 2006, Gastroenterology.

[4]  M. Sans,et al.  Starving the inflamed gut: Angiogenesis blockade as a novel therapeutic approach to experimental colitis , 2006 .

[5]  D. Podolsky.  Selective adhesion-molecule therapy and inflammatory bowel disease--a tale of Janus? , 2005, The New England journal of medicine.

[6]  J. Parrillo.  Severe sepsis and therapy with activated protein C. , 2005, The New England journal of medicine.

[7]  J. Planquois,et al.  New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated) , 2005, Critical care.

[8]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[9]  B. Dahlbäck,et al.  The anticoagulant protein C pathway , 2005, FEBS letters.

[10]  Hiroshi Yamamoto,et al.  The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. , 2005, The Journal of clinical investigation.

[11]  F. Castellino,et al.  A cardioprotective role for the endothelial protein C receptor in lipopolysaccharide-induced endotoxemia in the mouse. , 2005, Blood.

[12]  D. Binion,et al.  The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. , 2005, Inflammatory bowel diseases.

[13]  Jerry A Nick,et al.  Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. , 2004, Blood.

[14]  O. Feron,et al.  Innate immunity and angiogenesis. , 2004, Circulation research.

[15]  N. Blau,et al.  Gene Expression Profiling of Inflamed Human Endothelial Cells and Influence of Activated Protein C , 2004, Circulation.

[16]  D. Collen,et al.  Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  T. M. Gulik,et al.  Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats , 2004, Critical care medicine.

[18]  S. Danese,et al.  Platelets in Inflammatory Bowel Disease: Clinical, Pathogenic, and Therapeutic Implications , 2004, American Journal of Gastroenterology.

[19]  Tatsuya Hayashi,et al.  Protective role of activated protein C in lung and airway remodeling , 2004, Critical care medicine.

[20]  C. Esmon.  Structure and functions of the endothelial cell protein C receptor. , 2004, Critical care medicine.

[21]  N. Cordani,et al.  Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease , 2004, Critical care medicine.

[22]  T. van der Poll,et al.  Beyond sepsis: Activated protein C and ischemia–reperfusion injury , 2004, Critical care medicine.

[23]  C. Esmon.  Crosstalk between inflammation and thrombosis. , 2004, Maturitas.

[24]  B. Lambrecht,et al.  Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. , 2004, Blood.

[25]  H. Okabe,et al.  Activated protein C reduces stress‐induced gastric mucosal injury in rats by inhibiting the endothelial cell injury , 2004, Journal of thrombosis and haemostasis : JTH.

[26]  K. Okajima.  Regulation of inflammatory responses by activated protein C: the molecular mechanism(s) and therapeutic implications , 2004, Clinical chemistry and laboratory medicine.

[27]  C. Squiban,et al.  Inflammatory Reaction and Changes in Expression of Coagulation Proteins on Lung Endothelial Cells after Total-Body Irradiation in Mice , 2003, Radiation research.

[28]  C. Esmon.  The protein C pathway. , 2003, Critical care medicine.

[29]  Tatsuo Nakamura,et al.  Capillary Endothelial Thrombomodulin Expression and Fibrin Deposition in Rats with Continuous and Bolus Lipopolysaccharide Administration , 2003, Laboratory Investigation.

[30]  C. Esmon.  Inflammation and thrombosis , 2003, Journal of thrombosis and haemostasis : JTH.

[31]  C. A. de la Motte,et al.  Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. , 2003, Gastroenterology.

[32]  K. Mace,et al.  Engineering the proteolytic specificity of activated protein C improves its pharmacological properties , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Sandusky,et al.  Modulation of Thrombomodulin-dependent Activation of Human Protein C through Differential Expression of Endothelial Smads* , 2002, The Journal of Biological Chemistry.

[34]  V. Koteliansky,et al.  Collagen-binding integrin α1β1 regulates intestinal inflammation in experimental colitis , 2002 .

[35]  C. Esmon.  New Mechanisms for Vascular Control of Inflammation Mediated by Natural Anticoagulant Proteins , 2002, The Journal of experimental medicine.

[36]  P. Hellings,et al.  The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways , 2002, The Journal of experimental medicine.

[37]  M. Grisham,et al.  Immunological Basis of Inflammatory Bowel Disease: Role of the Microcirculation , 2001, Microcirculation.

[38]  C. Esmon.  Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation , 2001, Critical care medicine.

[39]  B. Grinnell,et al.  Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis , 2001, Critical care medicine.

[40]  L. Gelbert,et al.  Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis* , 2001, The Journal of Biological Chemistry.

[41]  B. Biedermann,et al.  Vascular endothelium: checkpoint for inflammation and immunity. , 2001, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[42]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[43]  J. Pucilowska,et al.  Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[44]  T. Noguchi,et al.  Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. , 2000, Blood.

[45]  M. Sans,et al.  VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. , 1999, Gastroenterology.

[46]  C. Fiocchi.  Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[47]  J. Panés,et al.  Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. , 1998, Gastroenterology.

[48]  L. Toy,et al.  Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease. , 1997, The Journal of clinical investigation.

[49]  C. Fiocchi.  Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[50]  K. Takatsuki,et al.  Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. , 1997, The American journal of physiology.

[51]  S. Collins.  The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. , 1996, Gastroenterology.

[52]  K. Takatsuki,et al.  Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. , 1996, Blood.

[53]  T. Springer,et al.  High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. , 1995, Immunology today.

[54]  Paul Kubes,et al.  The microcirculation and inflammation: modulation of leukocyte‐endothelial cell adhesion , 1994, Journal of leukocyte biology.

[55]  J. Griffin,et al.  Direct detection of activated protein C in blood from human subjects. , 1992, Blood.

[56]  D. Podolsky.  Inflammatory bowel disease (Second of two parts) , 1991 .

[57]  D. Mcclure,et al.  Characterization and Novel Purification of Recombinant Human Protein C from Three Mammalian Cell Lines , 1990, Bio/Technology.

[58]  C. Fiocchi,et al.  Interferon γ production by human intestinal mucosal mononuclear cells , 1988, Digestive Diseases and Sciences.

[59]  C. Fiocchi,et al.  Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel disease. , 1988, Digestive diseases and sciences.

[60]  A. Chang,et al.  Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. , 1987, The Journal of clinical investigation.

[61]  J. Griffin,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only. The cytoprotective protein C pathway , 2006 .

[62]  J. Willis,et al.  CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. , 2004, Gastroenterology.

[63]  J. Willis,et al.  Distinct inflammatory mechanisms mediate early versus late colitis in mice. , 2002, Gastroenterology.